271 related articles for article (PubMed ID: 23241739)
1. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
[TBL] [Abstract][Full Text] [Related]
2. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
3. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
Abidi MH; Agarwal R; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Ratanatharathorn V; Zonder J; Uberti J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):56-61. PubMed ID: 22892551
[TBL] [Abstract][Full Text] [Related]
4. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
[TBL] [Abstract][Full Text] [Related]
5. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.
Vadhan-Raj S; Trent J; Patel S; Zhou X; Johnson MM; Araujo D; Ludwig JA; O'Roark S; Gillenwater AM; Bueso-Ramos C; El-Naggar AK; Benjamin RS
Ann Intern Med; 2010 Sep; 153(6):358-67. PubMed ID: 20855800
[TBL] [Abstract][Full Text] [Related]
6. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
[TBL] [Abstract][Full Text] [Related]
7. Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
Jagasia MH; Abonour R; Long GD; Bolwell BJ; Laport GG; Shore TB; Durrant S; Szer J; Chen MG; Lizambri R; Waller EK
Bone Marrow Transplant; 2012 Oct; 47(10):1350-5. PubMed ID: 22327131
[TBL] [Abstract][Full Text] [Related]
8. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
9. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
10. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
[TBL] [Abstract][Full Text] [Related]
11. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E
Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.
Lucchese A; Matarese G; Ghislanzoni LH; Gastaldi G; Manuelli M; Gherlone E
Leuk Lymphoma; 2016; 57(4):820-7. PubMed ID: 26428409
[TBL] [Abstract][Full Text] [Related]
13. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
[TBL] [Abstract][Full Text] [Related]
14. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.
Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M
J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453
[TBL] [Abstract][Full Text] [Related]
15. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.
Henke M; Alfonsi M; Foa P; Giralt J; Bardet E; Cerezo L; Salzwimmer M; Lizambri R; Emmerson L; Chen MG; Berger D
J Clin Oncol; 2011 Jul; 29(20):2815-20. PubMed ID: 21670447
[TBL] [Abstract][Full Text] [Related]
16. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
17. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of incidence, clinical and quality of life consequences of oral mucositis post palifermin prophylaxis in patients undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Sakellari I; Angelopoulou M; Tsopra O; Dervenoulas I; Tsirigotis P; Spyridonidis A; Liga M; Tsionos K; Anargyrou K; Pouli A; Anagnostopoulos A
Ann Hematol; 2015 Oct; 94(10):1733-40. PubMed ID: 26141369
[TBL] [Abstract][Full Text] [Related]
19. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
20. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
Hassoun H; Flombaum C; D'Agati VD; Rafferty BT; Cohen A; Klimek VM; Boruchov A; Kewalramani T; Reich L; Nimer SD; Comenzo RL
Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]